Author: Rozalina Destanova
123jump.com
Last Update: 3:48 AM EDT May 28 2008
Revenue rose 57% to $4.66 billion, up from $2.98 billion, which included sales from Organon. The company acquired European drug developer Organon in November 2007. Sales of rheumatoid arthritis drug Remicade jumped 36% to $507 million, while sales of the allergy medication Nasonex increased 8% to $307 million. Sales of global cholesterol joint venture, which include cholesterol-controlling drugs Vytorin and Zetia, totaled $1.2 billion.
Sources: Data collected by 123jump.com and Ticker.com from company press releases, filings and corporate websites.
Market data: BATS Exchange. Inc.
350 Fund Managers Interviews - 10-year Annual earnings on 4,600 U.S. companies - 20-quarter Earnings on 3,800 U.S. companies - 3,200 U.S. IPO Prospectuses
- 2,100 Economic data releases from U.S., EU, UK, India, HK and Australia. 10-year Annual reports on 3,500 U.S. companies -
U.S. Earnings Calendar with 4,800 companies - 90,000 10-K reports - 26,000 Global markets news archive - 2,200 Earnings Conference Call Summaries